FibroBiologics
FBLG
63 hedge funds and large institutions have $11.9M invested in FibroBiologics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 4 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
3% more funds holding
Funds holding: 61 → 63 (+2)
0.08% more ownership
Funds ownership: 0.78% → 0.85% (+0.08%)
29% less capital invested
Capital invested by funds: $16.8M → $11.9M (-$4.95M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$377K |
| 2 |
State Street
Boston,
Massachusetts
|
+$265K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$228K |
| 4 |
Jane Street
New York
|
+$132K |
| 5 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SF
Symphony Financial
Houston,
Texas
|
-$75.8K |
| 2 |
CFP
Cascade Financial Partners
San Diego,
California
|
-$53.7K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$48.5K |
| 4 |
Morgan Stanley
New York
|
-$35.2K |
| 5 |
Millennium Management
New York
|
-$34.7K |
FBLG Hedge Fund Activity: Q4 2024 in Review
63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q4 2024, worth a combined $11.9M — down 29% from $16.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FBLG positions and 4 closed out — a net gain of 3 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $377K. The largest seller was Symphony Financial, exiting entirely with an estimated $75.8K sold.
- 63 institutional investors held FibroBiologics (FBLG) as of Q4 2024, up from 61 in Q3 2024.
- Funds reported $11.9M of FibroBiologics stock for Q4 2024, down 29% quarter-over-quarter.
- 7 funds opened new FibroBiologics positions in Q4 2024 and 4 closed out, a net change of +3 holders.
- The largest FibroBiologics buyer in Q4 2024 was Vanguard Group, an estimated $377K added.
- The largest FibroBiologics seller in Q4 2024 was Symphony Financial, an estimated $75.8K sold.
Based on aggregated 13F filings for Q4 2024.